secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001517022-26-000038
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia posts Q1 net loss of $9.1M; Vafseo revenue rises to $15.8M, patients up 60%
--------------------------------------------------------------------------------

- Net loss of $9.1M in Q1 2026 vs net income of $6.1M in Q1 2025; total revenues $53.5M, down from $57.3M.
- Vafseo net product revenue $15.8M (+31% YoY); patients on Vafseo increased 60% vs Q4 2025; prescribers up 28%.
- Auryxia net revenue $36.2M, down from $43.8M, with generic competition expected to expand in 2026.
- Cash $162.6M at March 31, 2026; company expects sufficient cash to fund operations for at least two years.
- Pipeline: praliciguat Phase 2 FSGS enrolling; AKB-097 basket study planned H2 2026; AKB-9090 Phase 1 initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000038/0001517022-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000038/akba-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001517022-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer